SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JULY 7, 1999
------------
ICN Pharmaceuticals, Inc.
-------------------------
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 001-11397 33-0628076
- -------------- --------- ----------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
3300 Hyland Avenue
Costa Mesa, California 92626
- ---------------------- ------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (714) 545-0100
--------------
N/A
-----------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
On July 7, 1999, the Registrant issued a press release announcing that
it intends to issue $100 million of Senior Notes through a private placement. On
July 20, 1999, the Registrant completed the private placement of $125 million of
Senior Notes.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ICN Pharmaceuticals, Inc.
By: /s/ David C. Watt
-----------------------------
David C. Watt
Executive Vice President,
General Counsel and
Secretary
Date: July 21, 1999
<PAGE>
EXHIBIT INDEX
Exhibit Number Description
- -------------- -----------
99.1 Text of Press Release issued by the Registrant on July 7, 1999.
ICN Pharmaceuticals Announces Proposed $100 Million
Debt Offering
NEW YORK, July 7 -- ICN Pharmaceuticals, Inc. (NYSE: ICN - news) today announced
that it intends to issue an additional $100 million of its 8-3/4% Senior Notes
due 2008 through a private placement. It is expected that the transaction will
close in July of this year. ICN intends to utilize the proceeds of the offering
for general corporate purposes including refinancing of existing corporate and
subsidiary debt, and acquisitions. The notes will not be registered under the
Securities Act and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements. This
announcement is neither an offer to sell nor a solicitation of an offer to buy
these securities. ICN manufactures and markets a broad range of prescription and
non-prescription pharmaceuticals and biotechnology research products in over 90
countries. The company employs some 13,000 people worldwide. ICN has operations
in North and Latin America, Western, Central and Eastern Europe, and the Pacific
Rim countries. Additional information is also available on the corporate website
at http://www.icnpharm.com.
- -----------------------
THE 'SAFE HARBOR' STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. This press release contains forward-looking statements that involve
risks and uncertainties including, but not limited to, projections of future
sales, operating income, returns on invested assets, regulatory approval
processes, financial impact of devaluations, the progress of FDA reviews, and
other risks detailed from time to time in the Company's Securities and Exchange
Commission filings.
